نتائج البحث - "García-Campelo, Rosario"

1

دورية أكاديمية

Improving quality of care by standardising patient data collection in electronic medical records in an oncology department in Spain

المؤلفون: Alonso-Jáudenes Curbera, Guillermo, Gómez-Randulfe Rodríguez, Martín Igor, Alonso de Castro, Beatriz, Silva Díaz, Sofía, Parajó Vázquez, Iria, Gratal, Paula, López López, Rafael, García Campelo, Rosario

المصدر: BMJ Open Quality ; volume 13, issue 2, page e002732 ; ISSN 2399-6641

الإتاحة: https://doi.org/10.1136/bmjoq-2023-002732Test

View record in BASE

2

دورية أكاديمية

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Nonâ€Smallâ€Cell Lung Cancer

المؤلفون: Riudavets, Mariona, Auclin, Edouard, Mosteiro, Miguel, Dempsey, Naomi, Majem, Margarita, Prelaj, Arsela, LÃ³pez-Castro, Rafael, Bosch-Barrera, Joaquim, Pilotto, Sara, Escalera, Elena, Tagliamento, Marco, Mosquera, Joaquin, Zalcman, GÃ©rard, Aboubakar Nana, Frank, Ponce, Santiago, AlbarrÃ¡n-Artahona, VÃctor, Dal Maso, Alessandro, Spotti, Martina, Mielgo, Xabier, Mussat, Elodie, Reyes, Roxana, BenÃtez, Jose-Carlos, Lupinacci, Lorena, Duchemann, Boris, De Giglio, Andrea, Blaquier, Juan Bautista, Audigier-Valette, Clarisse, Scheffler, Matthias, Nadal, Ernest, Lopes, Gilberto, Signorelli, Diego, Garcia-Campelo, Rosario, Menis, Jessica, Bluthgen, Virginia, Campayo, Marc, Recondo, Gonzalo, Besse, Benjamin, Mezquita, Laura, Planchard, David

المساهمون: UCL - SSS/IREC/LUNS - PÃ´le pneumologie, ORL (airways) et dermatologie (skin), UCL - (SLuc) Service de pneumologie

المصدر: Clinical Lung Cancer, Vol. 25, no.3, p. 233-243.e8 (2024)

مصطلحات موضوعية: Consolidation, Durvalumab, Host-related biomarkers, LIPI, Stage III

العلاقة: boreal:288103; http://hdl.handle.net/2078.1/288103Test; urn:ISSN:1525-7304

الإتاحة: https://doi.org/10.1016/j.cllc.2023.11.007Test
http://hdl.handle.net/2078.1/288103Test

View record in BASE

3

دورية أكاديمية

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

المصدر: Archivos de Bronconeumología ; volume 60, issue 2, page 88-94 ; ISSN 0300-2896

مصطلحات موضوعية: Pulmonary and Respiratory Medicine

الإتاحة: https://doi.org/10.1016/j.arbres.2023.12.005Test
https://api.elsevier.com/content/article/PII:S0300289623004076?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0300289623004076?httpAccept=text/plainTest

View record in BASE

4

دورية أكاديمية

Difficulties on the acces to innovative targeted therapies for lung cancer in Spain

المؤلفون: Calvo, Virginia, Camps Herrero, Carlos, Carcereny, Enric, Cobo, Manuel, Dómine, Manuel, Garcia Campelo, Rosario, González Larriba, Jose Luís, Guirado, Maria, Hernando Trancho, Florentino, Massuti Sureda, Bartomeu, Nadal, Ernest, Rodriguez-Abreu, Delvys, Sánchez, Alfredo, Sullivan, Ivana, Provencio Pulla, Mariano

مصطلحات موضوعية: Càncer, Medicina Pràctica professional, Pulmons Malalties

وصف الملف: application/pdf

العلاقة: Clinical & Translational Oncology, 2023; Calvo, Virginia Camps Herrero, Carlos Carcereny, Enric Cobo, Manuel Dómine, Manuel Garcia Campelo, Rosario González Larriba, Jose Luís Guirado, Maria Hernando Trancho, Florentino Massuti Sureda, Bartomeu Nadal, Ernest Rodriguez-Abreu, Delvys Sánchez, Alfredo Sullivan, Ivana Provencio Pulla, Mariano 2023 Difficulties on the acces to innovative targeted therapies for lung cancer in Spain Clinical & Translational Oncology; https://hdl.handle.net/10550/89077Test; 161071

الإتاحة: https://doi.org/10.1007/s12094-023-03303-5Test
https://hdl.handle.net/10550/89077Test

View record in BASE

5

دورية أكاديمية

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

المؤلفون: Bernabé-Caro, Reyes, Garrido, Pilar, García Campelo, Rosario, Palmero, Ramón, Artal, Ángel, Bayona, Cristina, Castro, Javier de

المساهمون: Universidad de Sevilla. Departamento de Medicina

مصطلحات موضوعية: ALK-positive NSCLC, ALK inhibitor, crizotinib, alectinib, unselected patient

العلاقة: Oncotarget, 13 (1), 812-827.; https://www.oncotarget.com/article/28244/textTest/; https://idus.us.es/handle//11441/146634Test

الإتاحة: https://idus.us.es/handle//11441/146634Test

View record in BASE

6

دورية أكاديمية

Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer.

المساهمون: UCL - SSS/IREC/PNEU - PÃ´le de Pneumologie, ORL et Dermatologie, UCL - SSS/DDUV/GECE - GÃ©nÃ©tique cellulaire, UCL - (SLuc) Service de pneumologie

المصدر: Lung cancer, Vol. 178, p. 116-122 (2023)

مصطلحات موضوعية: Humans, Female, Middle Aged, Male, Carcinoma, Non-Small-Cell Lung, Retrospective Studies, Lung Neoplasms, Immunotherapy, Progression-Free Survival, Taxoids, Antineoplastic Combined Chemotherapy Protocols, Chemo-immunotherapy, Non small cell lung cancer, Prognosis, Second line, Survival

العلاقة: boreal:278884; http://hdl.handle.net/2078.1/278884Test; info:pmid/36812760; urn:ISSN:0169-5002; urn:EISSN:1872-8332

الإتاحة: https://doi.org/10.1016/j.lungcan.2023.02.002Test
http://hdl.handle.net/2078.1/278884Test

View record in BASE

7

دورية أكاديمية

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

المؤلفون: Besse, Benjamin, Garcia Campelo, Rosario, cobo, manuel, Mascaux, C, Madroszyk, Anne, FELIP, ENRIQUETA

المساهمون: Institut Català de la Salut, Besse B Paris-Saclay University, Cancer Medicine Department, Institut Gustave Roussy, Villejuif, France. Felip E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Garcia Campelo R Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, Biomedical Research Institute, INIBIC, A Coruña. Cobo M Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. Mascaux C Pneumology Department, Hôpitaux Universitaires de Strasbourg—Nouvel Hôpital Civil, Strasbourg. Madroszyk A Medical Oncology Department, IPC—Institut Paoli-Calmettes, Marseille, France, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Pulmons - Càncer - Tractament, Vacunes contra el càncer, Antígens HLA, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, CHEMICALS AND DRUGS::Complex Mixtures::Biological Products::Vaccines::Cancer Vaccines, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Histocompatibility Antigens Class I::HLA-A Antigens::HLA-A2 Antigen, PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::productos biológicos::vacunas::vacunas del cáncer, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::glicoproteínas::glicoproteínas de membranas::antígenos de histocompatibilidad de clase I::antígenos HLA-A::antígeno HLA-A2, FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos

وصف الملف: application/pdf

العلاقة: Annals of Oncology;34(10); https://doi.org/10.1016/j.annonc.2023.07.006Test; Besse B, Felip E, Garcia Campelo R, Cobo M, Mascaux C, Madroszyk A, et al. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol. 2023 Sep 11;34(10):920–33.; https://hdl.handle.net/11351/10395Test

الإتاحة: https://doi.org/10.1016/j.annonc.2023.07.006Test
https://hdl.handle.net/11351/10395Test

View record in BASE

النص الكامل

8

دورية أكاديمية

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

المؤلفون: Ready, Neal, Audigier-Valette, Clarisse, Goldman, Jonathan W., Felip Font, Enriqueta, Ciuleanu, Tudor, Garcia Campelo, Rosario

المساهمون: Institut Català de la Salut, Ready NE Department of Medicine, Duke University, Durham, North Carolina, USA. Audigier-Valette C Division of Pneumo-Oncology, Hôpital Sainte Musse, Toulon, Provence-Alpes-Côte d'Azur, France. Goldman JW Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Felip E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Ciuleanu TE Department of Oncology, Oncology Institute Prof Dr Ion Chiricuta, Cluj-Napoca, Romania. University of Medicine and Pharmacy Iuliu Hațieganu, Cluj-Napoca, Romania. Rosario García Campelo M Medical Oncology Unit, University Hospital A Coruña (XXIAC-SERGAS), A Coruña, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Pulmons - Càncer - Tractament, Quimioteràpia combinada, Avaluació de resultats (Assistència sanitària), DISEASES::Respiratory Tract Diseases::Lung Diseases::Lung Neoplasms::Carcinoma, Bronchogenic::Respiratory Tract Diseases::Carcinoma, Non-Small-Cell Lung, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols, Other subheadings::Other subheadings::/therapeutic use, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada, Otros calificadores::Otros calificadores::/uso terapéutico, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: Journal for ImmunoTherapy of Cancer;11(2); http://dx.doi.org/10.1136/jitc-2022-006127Test; Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, García Campelo MR, et al. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer. 2023 Feb;11(2):e006127.; https://hdl.handle.net/11351/9107Test

الإتاحة: https://doi.org/10.1136/jitc-2022-006127Test
https://hdl.handle.net/11351/9107Test

View record in BASE

النص الكامل